Content area
Abstract
Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the European Society of Cardiology in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.
Details
; Bilato, Claudio 4 ; Mollace, Vincenzo 5 ; Pasquale Perrone Filardi 6 ; Rosano, Giuseppe M C 3 1 Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Bern, Switzerland; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Drexel University College of Medicine, Philadelphia, PA, USA
2 University of Warwick, Coventry CV4 7AL, UK; Monash University, Melbourne, Australia
3 Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Via della Pisana, 235, 00163 Rome, Italy
4 Division of Cardiology, West Vicenza General Hospitals, Vicenza, Italy
5 Institute for Food Safety & Health University, ‘Magna Graecia of Catanzaro’, Catanzaro, Italy
6 Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy